Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.
about
Oestrogen therapy for urinary incontinence in post-menopausal womenOestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal womenRisk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.Pharmacology and clinical applications of selective estrogen receptor modulators.Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update.Prevention and treatment of postmenopausal osteoporosis.Cardiovascular effects of raloxifene: the potential for cardiovascular protection in women.Is there a future for selective estrogen-receptor modulators in osteoporosis?Statins and osteoporosis: a clinical review.Lasofoxifene (CP-336,156), a novel selective estrogen receptor modulator, in preclinical studies.Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifeneWhere are we with postmenopausal hormone therapy in 2005?Recommendations for raloxifene use in daily clinical practice in the Swiss setting.Variations in nanomechanical properties and tissue composition within trabeculae from an ovine model of osteoporosis and treatment.For the first fracture to be the last.Osteoporosis: prevention and treatment in anorexia nervosa.Current and emerging therapies for the treatment of osteoporosisRaloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice.Histone methyltransferases and demethylases: regulators in balancing osteogenic and adipogenic differentiation of mesenchymal stem cells.Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy.Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy.SERMs and SERMs with estrogen for postmenopausal osteoporosis.Osteoporosis update: effective prevention and treatment.The clinical use of denosumab for the management of low bone mineral density in postmenopausal women.Neurocognitive, Neuroprotective, and Cardiometabolic Effects of Raloxifene: Potential for Improving Therapeutic Outcomes in Schizophrenia.Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/lipoproteins.Associated response in bone mineral density and atherogenic lipid profile during treatment with two different selective estrogen receptor modulators: levormeloxifene and raloxifene.Osteoporosis guidelines.Raloxifene: a selective estrogen-receptor modulator for postmenopausal osteoporosis - a clinical update on efficacy and safety.Serum lipids and apolipoproteins in Greek postmenopausal women: association with estrogen, estrogen-progestin, tibolone and raloxifene therapy.Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women.Estrogen receptor alpha-mediated adiposity-lowering and hypocholesterolemic actions of the selective estrogen receptor modulator acolbifene.Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women.Osteoporosis guidelines.Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial.Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.Toll-like receptor 2 activation primes and upregulates osteoclastogenesis via lox-1.The Role of Semipurified Fractions Isolated from Quercus infectoria on Bone Metabolism by Using hFOB 1.19 Human Fetal Osteoblast Cell Model.
P2860
Q24198065-431CFE4A-7456-429D-9310-05C788F1CEEFQ24235377-43A5700C-347B-4F11-9118-48E4CD1D06C3Q30940476-CFF1AE17-1682-4DF3-9D4E-AFF628A43F88Q33384192-03C36040-75E0-4086-9C62-88E66E96B55BQ34272056-1187449B-BC74-494A-B2DA-D11A67AB49EBQ34296614-253E755F-9EEA-4A53-872E-9D38AA0F1482Q34669339-FB2D777A-CFFA-417E-A6A6-A9C74EE6452FQ36059531-5B131E2A-0EE7-4DF9-B1D5-99DE2BD84E21Q36070930-3F80DA85-CFA0-4C95-AF89-D7A95B3BCD36Q36271670-EC2860DA-E0EB-4DEF-8422-7EB7EAC83F3CQ36334805-47A8B97B-919A-4131-8267-EC9AEEAA31DDQ36350786-C915D573-C40F-4E46-A7C8-B8FBA9ECB71FQ36428565-96B59724-AF9B-4BA5-A352-65EEB7B4555FQ36729340-6D7FC38D-FACF-437C-B99A-9E585122741CQ36740535-52F0B3FB-9230-4634-9CB9-8DBAF5EBD3EFQ36888634-7D939923-AED3-4ED1-94F1-EB06BF36D75EQ36890431-20E68525-1EA0-4E00-A17F-88B8DCD17CC6Q37203948-B15A7AD9-1A7D-402F-8EA1-7068F6D355D7Q37497415-A6B8436B-A559-4F85-BBCE-1F5072E4C037Q37677579-C454A40D-DFCD-4786-BBD1-DD0AA238CF2EQ37731292-67F0AC5D-3326-44B9-B114-688AB709ECC1Q37743272-7A5ED38A-A9BB-4F1A-A42D-2C02FDDA5B54Q37763162-2606E024-B35C-495E-9915-0F2328F05A87Q38006918-D57BDBD5-85C2-4D00-9C7C-4A9964033536Q38837641-8066E53B-2F65-40DF-9EBD-F4E22D6AFD74Q40579083-99401B09-DEED-4D3E-991C-121F92940D87Q42166397-8460CD58-E801-49F9-8DA6-AE60137B23CEQ42875457-3EA121FF-DF20-4A21-A32C-D8DCEE656E35Q43267067-C63E2D94-C20B-4B2B-8D47-1F4164BF464CQ44571336-61CDE319-A504-47EA-82C7-85445A4600FAQ45043374-74A9222C-1FC2-4E2C-8EF0-D47513104D3DQ46519012-812EF610-7EA7-4D3D-B636-B0C690A571C7Q46746525-C7D0AD93-23F6-4239-BE16-6FBEBAE70C3DQ50426831-1BC896FB-B151-46AF-914C-886E3BA8395BQ51194691-5846C14D-18BD-4F60-8B8F-B70D5B0B1318Q53736162-EB4F7EDD-DFED-4A79-B2CC-C30CC62A26EBQ54977323-210F8B67-F762-4DF7-BDC9-F8A68FC3B306Q55074138-B7C9855B-5864-4798-AF6A-37A514A51D82
P2860
Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Long-term effects of raloxifen ...... ed, placebo-controlled trials.
@ast
Long-term effects of raloxifen ...... ed, placebo-controlled trials.
@en
type
label
Long-term effects of raloxifen ...... ed, placebo-controlled trials.
@ast
Long-term effects of raloxifen ...... ed, placebo-controlled trials.
@en
prefLabel
Long-term effects of raloxifen ...... ed, placebo-controlled trials.
@ast
Long-term effects of raloxifen ...... ed, placebo-controlled trials.
@en
P2093
P1476
Long-term effects of raloxifen ...... ed, placebo-controlled trials.
@en
P2093
Bjarnason NH
Christiansen C
Heath H 3rd
P304
P356
10.1001/ARCHINTE.160.22.3444
P407
P577
2000-12-01T00:00:00Z